Digest Network Come funziona
Network
/
Società
Au
Non verificato

Autobahn Therapeutics

Di cosa scriviamo

BiotecnologiaEventiFarmaceuticaMedicina - VarieSalute

10 comunicati stampa

Guarda tutti i comunicati
10/11/2025
Biotecnologia
Psichiatria
Salute
Farmaceutica
Eventi
Autobahn Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
Fonte
Autobahn Therapeutics
Emittente
Business Wire
1.00
0
08/07/2025
Psichiatria
Salute
Scienza
Farmaceutica
Biotecnologia
Eventi
Autobahn Therapeutics to Participate in Evercore’s Emerging Private Biotech Conference
Fonte
Autobahn Therapeutics
Emittente
Business Wire
1.00
0
27/05/2025
Eventi
Biotecnologia
Psichiatria
Salute
Farmaceutica
Autobahn Therapeutics to Participate in Jefferies Global Healthcare Conference
Fonte
Autobahn Therapeutics
Emittente
Business Wire
1.00
0
23/05/2025
Eventi
Industria
Psichiatria
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Autobahn Therapeutics Announces Presentation of ABX-002 Phase 1 Clinical Results at the 2025 ASCP Annual Meeting
Fonte
Autobahn Therapeutics
Emittente
Business Wire
1.00
0
08/01/2025
Industria
Biotecnologia
Psichiatria
Salute
Farmaceutica
Medicina - Varie
Autobahn Therapeutics Announces Initiation of Phase 2 Trial of ABX-002 as an Adjunctive Treatment for Bipolar Depression
Fonte
Autobahn Therapeutics
Emittente
Business Wire
1.00
0
12/11/2024
Psichiatria
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Eventi
Finanza
Autobahn Therapeutics to Participate in Multiple Upcoming Investor Conferences
Fonte
Autobahn Therapeutics
Emittente
Business Wire
1.00
0
22/10/2024
Industria
Psichiatria
Salute
Igiene alimentare
Medicina - Varie
Farmaceutica
Biotecnologia
Autobahn Therapeutics Announces FDA Clearance of IND Application for ABX-002 as an Adjunctive Treatment for Bipolar Depression
Fonte
Autobahn Therapeutics
Emittente
Business Wire
1.00
0
16/09/2024
Industria
Biotecnologia
Psichiatria
Salute
Farmaceutica
Medicina - Varie
Autobahn Therapeutics Announces Initiation of its AMPLIFY Phase 2 Trial of ABX-002 as an Adjunctive Treatment for Major Depressive Disorder
Fonte
Autobahn Therapeutics
Emittente
Business Wire
1.00
0
10/09/2024
Eventi
Biotecnologia
Farmaceutica
Comunicazione
Sanità
Salute
Medicina - Varie
Autobahn Therapeutics to Participate in Multiple Upcoming Investor Conferences
Fonte
Autobahn Therapeutics
Emittente
Business Wire
1.00
0
24/07/2024
Psichiatria
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Autobahn Therapeutics Completes Oversubscribed $100 Million Series C Financing to Advance Pipeline of Novel Therapeutics for Depression and Other CNS Disorders
Fonte
Autobahn Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0